Chronic hepatitis C and liver fibrosis

Area of Science:

• Hepatology
• Virology
• Gastroenterology

Background:

• Chronic hepatitis C virus (HCV) infection is a major global cause of liver disease, leading to fibrosis and complications.
• Liver fibrosis, an excessive accumulation of extracellular matrix, is a response to chronic liver injury and critical for disease staging.
• Accurate staging of liver fibrosis is essential for managing chronic hepatitis C (CHC) patients, a growing population with significant healthcare needs.

Purpose of the Study:

• To review HCV epidemiology and the mechanisms of HCV-induced liver fibrogenesis.
• To discuss and compare methods for assessing liver fibrosis in clinical practice.
• To highlight the growing role and benefits of non-invasive fibrosis assessment methods.

Main Methods:

• Review of current literature on HCV epidemiology and fibrogenesis.
• Discussion of traditional methods like liver biopsy and newer non-invasive techniques.
• Analysis of clinical studies evaluating non-invasive fibrosis assessment tools.

Main Results:

• Non-invasive methods, including serum biomarkers and transient elastography, demonstrate high accuracy in diagnosing and monitoring liver fibrosis.
• These non-invasive approaches offer significant prognostic value and cost-effectiveness compared to liver biopsy.
• Clinical studies confirm the reliability of non-invasive methods for CHC patient management.

Conclusions:

• Non-invasive methods for liver fibrosis assessment are increasingly adopted in clinical guidelines.
• These methods are becoming the standard of care, reducing the need for invasive liver biopsies.
• The shift towards non-invasive assessment improves patient outcomes and healthcare efficiency in managing chronic hepatitis C.